CMPS trades within a ±12% band through September absent a named Phase 3 readout; the 1.9% pop fully mean-reverts within 15 trading days.

Shares of COMPASS Pathways (ticker: CMPS), a company developing a synthetic psilocybin pill called COMP360, recently jumped about 2% for no clear reason. That small gain will likely disappear within three weeks, and the stock will drift sideways — up or down no more than 12% — until the company releases results from its large Phase 3 trial (the final, decisive round of human testing required before a drug can be approved). Nothing meaningful has changed about the company; the price move was just random market noise.

No catalyst underlies today's move. Retail-driven noise reverts. Institutional capital waits for COMPASS COMP360 pivotal data, not headlines.